Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Total Current Liabilities: 2023-2024

Historic Total Current Liabilities for BioLineRx (BLRX) over the last 2 years, with Dec 2024 value amounting to $15.4 million.

  • BioLineRx's Total Current Liabilities fell 49.28% to $15.5 million in Q2 2025 from the same period last year, while for Jun 2025 it was $15.5 million, marking a year-over-year decrease of 49.28%. This contributed to the annual value of $15.4 million for FY2024, which is 63.99% down from last year.
  • As of FY2024, BioLineRx's Total Current Liabilities stood at $15.4 million, which was down 63.99% from $42.8 million recorded in FY2023.
  • BioLineRx's 5-year Total Current Liabilities high stood at $42.8 million for FY2023, and its period low was $15.4 million during FY2024.
  • Moreover, its 2-year median value for Total Current Liabilities was $29.1 million (2023), whereas its average is $29.1 million.
  • Data for BioLineRx's Total Current Liabilities shows a maximum YoY tumbled of 63.99% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows BioLineRx's Total Current Liabilities stood at $42.8 million in 2023, then plummeted by 63.99% to $15.4 million in 2024.